Robert J. Israel

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Role not yet determined Is this you? Add your title

UAMS

Also affiliated: Brigham and Women's Hospital (2024); City Of Hope National Medical Center (2007–2009); Memorial Sloan Kettering Cancer Center (1990); Harvard University (2024); Cornell University (1986); North Shore University Hospital (1986); University of Chicago (2006); Bausch Health (United States) (2017–2023); City of Hope (2007–2009); Progenics Pharmaceuticals (United States) (2006–2014); University of South Alabama Medical Center (2024); Salix Pharmaceuticals (United States) (2024); University of South Alabama (2024)

16 h-index 52 pubs 949 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Robert J. Israel's research has focused on pharmacological interventions and clinical studies, with a notable emphasis on treatments for opioid-induced constipation and respiratory conditions. He has investigated the efficacy and safety of subcutaneous methylnaltrexone in both cancer and non-cancer patients, analyzing variables across multiple studies. Additionally, Israel has explored the use of ribavirin aerosol for treating SARS-CoV-2 in hospitalized adults, including a randomized, placebo-controlled study on its safety and pharmacokinetics. His work also includes an analysis of methylnaltrexone's central nervous system effects in patients with brain metastases and a thorough QT study evaluating the cardiac safety of amiselimod.

His scholarship metrics include an h-index of 16, with 59 total publications and over 1,033 citations. Israel has collaborated with researchers such as Sara C. Shalin, Belin F Bodies, and Thomas C Myers at the University of Arkansas for Medical Sciences. His most recent publication was in 2024, indicating recent activity in his research pursuits.